AMENDMENT #1 TO LICENSE AGREEMENT ID 2014-0052 Between Purdue Research Foundation and Endocyte, Inc.License Agreement • May 10th, 2017 • Endocyte Inc • Pharmaceutical preparations
THIS AMENDMENT, made and entered into this 29th day of June, 2015 (“Amendment Effective Date”) amends the Master License Agreement entered into and effective as of July 1, 2013 and all subsequent Amendments (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte, Inc. (hereinafter known as LICENSEE) with respect to the matters addressed in this Agreement.
AMENDMENT #14License Agreement • May 10th, 2017 • Endocyte Inc • Pharmaceutical preparations
THIS AMENDMENT, made and entered into this 30'" day of January, 20 I 5 ("Amendment Effective Date") amends the Amended and Restated License Agreement executed on October 21st, 1998, and all subsequent Amendments (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte Corporation (hereinafter known as LICENSEE) with respect to the matters addressed in this Agreement.
Second Amendment to the Amended and Restated License Agreement made effective on March 1, 2010 between the Purdue Research Foundation and Endocyte, Inc. (“Agreement”)License Agreement • May 10th, 2017 • Endocyte Inc • Pharmaceutical preparations
This second amendment (“Amendment”), made and entered effective as of the 1st day of March, 2010 (the “Effective Date”) between Endocyte, Inc., with a place of business at 3000 Kent Avenue, Suite A1-100, West Lafayette, IN 47906 (“Client”), and, Purdue Research Foundation, having a place of business at 1281 Win Hentschel Blvd., West Lafayette, IN 47906.
